Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial
- Xiaowei Zhang
- Ting Zhao
- Midie Xu
- Yanjing Guo
- Qifeng Wang
- Yanli Wang
- Liangping Zhou
- Silong Hu
- Qinghua Xu
- Xichun Hu
- Xin Liu
- Zhiguo Luo
2026-05-09